Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatments have same target, different responses for lung cancer patients with genetic mutation

17.08.2005


The gene mutation that identifies the lung cancer patients most likely to respond to the drug gefitinib (Iressa) is not associated with a response to the drug cetuximab (Erbitux), according to a new study published in the August 17 issue of the Journal of the National Cancer Institute. Both drugs target the same gene but through different mechanisms.

Some patients with non–small-cell lung cancer (NSCLC) have mutant versions of the epidermal growth factor receptor (EGFR). This protein activates signaling pathways involved with cell growth and survival. Previous studies have shown that small-molecule EGFR inhibitors such as gefitinib and erlotinib (Tarceva) work by blocking signals in the intracellular domain of EGFR--between the EGFR and the cell nucleus. Additionally, many NSCLC patients with mutations in this intracellular domain of EGFR appear to benefit from these drugs.

Toru Mukohara, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues decided to examine the effectiveness of another type of drug that targets EGFR--a monoclonal antibody called cetuximab, which is approved for the treatment of metastatic colorectal cancers that overexpress EGFR. Cetuximab targets EGFR by preventing its activation by extracellular signals, or signals occurring outside of the cell, as opposed to the intra-cellular signal blocking of drugs like gefitinib.



The researchers treated seven different NSCLC cell lines with cetuximab or gefitinib, and compared the drugs’ effects on cell growth and cell death or apoptosis. They found that both drugs similarly inhibited the growth of the NSCLC cells containing the normal form of EGFR. However, gefitinib was more effective than cetuximab at inhibiting cell growth and increasing apoptosis in NSCLC cells with mutant EGFR.

The authors note that because these studies were carried out in cell lines, and not in humans, issues such as which drug has more toxicity or negative side effects are still unanswered. However, they did examine the outcomes of four patients with EGFR mutations in their tumors who had been treated with gefitinib and then cetuximab, or vice versa. They found that all patients displayed partial responses to gefitinib in terms of tumor shrinkage, whereas none of them appeared to respond to cetuximab.

"Overall, our results raise the possibility that NSCLC patients with EGFR mutations may derive the greatest benefit, in terms of tumor regression, if treated with gefitinib rather than with cetuximab," the authors conclude.

"These findings clearly have important clinical implications because both drugs should, theoretically, block EGFR signaling," writes John D. Minna, M.D., of the Hamon Center for Therapeutic Oncology Research at the University of Texas Southwestern Medical Center in Dallas, and colleagues in an accompanying editorial. "The first round clearly was won by [drugs such as gefitinib]." However, they add that additional research should focus on the effects of cetuximab on certain populations of patients, or used in conjunction with other drugs. "Cetuximab may still have an effective punch if the right circumstances can be identified," the authors conclude.

Elana Hayasaka | EurekAlert!
Further information:
http://www.oupjournals.org

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>